Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study

References

• Briere JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007;2:3.
   PubMed Web of Science ®Google Scholar
• Scherber RM, Mesa RA. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018;2018(1):118–126.
   PubMedGoogle Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Zahr AA, Salama ME, Carreau N, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660–671.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.
   PubMed Web of Science ®Google Scholar
• Mitra D, Kaye JA, Piecoro LT, et al. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. Cancer Med. 2013;2(6):889–898.
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–408.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96(10):1653–1665.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelo Fibrosis Research and Treatment. Blood. 2009;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–1613.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology, Myeloproliferative Neoplasms, version 2, Plymouth Meeting, PA:NCCN; 2022.
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Health Qual Life Outcomes. 2009;4:79.
   Google Scholar
• U.S. Department of Health Human Services FDA Center for Drug Evaluation Research, U.S. Department of Health Human Services FDA Center for Biologics Evaluation Research, U.S Department of health human services FDA center for devices radiological health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
   PubMed Web of Science ®Google Scholar
• Messina A, O'Brien Q, Andrianov V, et al. Under reporting of patient reported outcomes (PROs) in myeloproliferative neoplasm (MPN) clinical trials. Blood. 2019;134(Suppl. 1):4754.
   Google Scholar
• Gerds AT, Lyons RM, Colucci P, et al. Disease and clinical characteristics of patients with a clinical diagnosis of myelofibrosis enrolled in the MOST study. Clin Lymphoma Myeloma Leuk. 2022;22(7):e532–e540.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Lyons R, Verstovsek S, et al. Disease and clinical characteristics of patients with a clinical diagnosis of essential thrombocythemia enrolled in the MOST study. Clin Lymphoma Myeloma Leuk. 2021;21(7):461–469.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–396.
   PubMed Web of Science ®Google Scholar
• Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90(10):864–870.
   PubMed Web of Science ®Google Scholar
• Scherber RM, Kosiorek HE, Senyak Z, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–485.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–3810.
   PubMed Web of Science ®Google Scholar
• Scherber RM, Geyer H, Harrison CN, et al. Impact of disease duration upon symptom burden amongst patients with myeloproliferative neoplasms (MPNs). Blood. 2015;126(23):4073–4073.
   Google Scholar
• Sudore RL, Karter AJ, Huang ES, et al. Symptom burden of adults with type 2 diabetes across the disease course: diabetes & aging study. J Gen Intern Med. 2012;27(12):1674–1681.
   PubMed Web of Science ®Google Scholar
• Djarv T, Wikman A, Lagergren P. Number and burden of cardiovascular diseases in relation to health-related quality of life in a cross-sectional population-based cohort study. BMJ Open. 2012;2(5):e001554.
   PubMed Web of Science ®Google Scholar
• Zambroski CH, Moser DK, Bhat G, et al. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4(3):198–206.
   PubMedGoogle Scholar
• Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017;102(1):85–93.
   PubMed Web of Science ®Google Scholar
• Samulowitz A, Gremyr I, Eriksson E, et al. "Brave men" and "emotional women": a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res Manag. 2018;2018:6358624.
   PubMed Web of Science ®Google Scholar
• Zubieta JK, Smith YR, Bueller JA, et al. Mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22(12):5100–5107.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Campbell CM, Edwards RR, et al. Sex-based differences in pain perception and treatment. Pain Med. 2009;10(2):289–299.
   PubMed Web of Science ®Google Scholar
• Delaruelle Z, Ivanova TA, Khan S, et al. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19(1):117.
   PubMed Web of Science ®Google Scholar
• Glinskii OV, Huxley VH, Glinsky VV. Estrogen-dependent changes in dura mater microvasculature add new insights to the pathogenesis of headache. Front Neurol. 2017;8:549.
   PubMed Web of Science ®Google Scholar
• Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–514.
   PubMed Web of Science ®Google Scholar
• Stein BL, Rademaker A, Spivak JL, et al. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis. 2011;2011:874146.
   PubMedGoogle Scholar
• Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.
   PubMed Web of Science ®Google Scholar
• Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726.
   PubMed Web of Science ®Google Scholar
• Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228–242.
   PubMed Web of Science ®Google Scholar
• McFarland DC, Shaffer KM, Polizzi H, et al. Prevalence of physical problems detected by the distress thermometer and problem list in patients with myeloproliferative disorders. J Natl Compr Canc Netw. 2017;15(12):1503–1508.
   PubMed Web of Science ®Google Scholar
• Riba MB, Donovan KA, Andersen B, et al. Distress management, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(10):1229–1249.
   PubMed Web of Science ®Google Scholar
• Peseski AM, Saliba AN, Althouse SK, et al. Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms? Hematol Oncol Stem Cell Ther. 2021. Epub ahead of print.
   PubMedGoogle Scholar
• Niksic M, Rachet B, Warburton FG, et al. Ethnic differences in cancer symptom awareness and barriers to seeking medical help in England. Br J Cancer. 2016;115(1):136–144.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123(3):449–458.
   PubMed Web of Science ®Google Scholar
• Yu J, Parasuraman S, Paranagama D, et al. Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018;18(1):420.
   PubMedGoogle Scholar
• Robinson AJ, Godfrey AL. Low-risk essential thrombocythemia: a comprehensive review. Hemasphere. 2021;5(2):e521.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Cattaneo D. Treatment of myelofibrosis: old and new strategies. Clin Med Insights Blood Disord. 2017;10:1179545X17695233.
   PubMedGoogle Scholar